Skip to main content
Passa alla visualizzazione normale.

GIUSEPPE BADALAMENTI

KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study

  • Authors: Incorvaia, Lorena; De Biase, Dario; Nannini, Margherita; Fumagalli, Elena; Vincenzi, Bruno; De Luca, Ida; Brando, Chiara; Perez, Alessandro; Pantaleo, Maria A; Gasperoni, Silvia; D'Ambrosio, Lorenzo; Grignani, Giovanni; Maloberti, Thais; Pedone, Erika; Bazan Russo, Tancredi Didier; Mazzocca, Alessandro; Algeri, Laura; Dimino, Alessandra; Barraco, Nadia; Serino, Roberta; Gristina, Valerio; Galvano, Antonio; Bazan, Viviana; Russo, Antonio; Badalamenti, Giuseppe
  • Publication year: 2023
  • Type: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/603934

Abstract

Background The patient selection for optimal adjuvant therapy in gastrointestinal stromal tumors (GISTs) is provided by nomogram based on tumor size, mitotic index, tumor location, and tumor rupture. Although mutational status is not currently used to risk assessment, tumor genotype showed a prognostic influence on natural history and tumor relapse. Innovative measures, such as KIT/PDGFRA-mutant-specific variant allele frequency (VAF) levels detection from next-generation sequencing (NGS), may act as a surrogate of tumor burden and correlate with prognosis and overall survival of patients with GIST, helping the choice for adjuvant treatment. Patients and Methods This was a multicenter, hospital-based, retrospective/prospective cohort study to investigate the prognostic role of KIT or PDGFRA-VAF of GIST in patients with radically resected localized disease. In the current manuscript, we present the results from the retrospective phase of the study. Results Two-hundred (200) patients with GIST between 2015 and 2022 afferent to 6 Italian Oncologic Centers in the EURACAN Network were included in the study. The receiver operating characteristic (ROC) curves analysis was used to classify "low" vs. "high" VAF values, further normalized on neoplastic cellularity (nVAF). When RFS between the low and high nVAF groups were compared, patients with GIST with KIT/PDGFRA nVAF > 50% showed less favorable RFS than patients in the group of nVAF & LE; 50% (2-year RFS, 72.6% vs. 93%, respectively; P = .003). The multivariable Cox regression model confirmed these results. In the homogeneous sub-population of intermediate-risk, patients with KIT-mutated GIST, the presence of nVAF >50% was statistically associated with higher disease recurrence. Conclusion In our study, we demonstrated that higher nVAF levels were independent predictors of GIST prognosis and survival in localized GIST patients with tumors harboring KIT or PDGFRA mutations. In the cohort of intermediate-risk patients, nVAF could be helpful to improve prognostication and the use of adjuvant imatinib.Innovative measures, such as KIT/PDGFRA -mutant-specific variant allele frequency levels detection from next-generation sequencing, could act as a surrogate of tumor burden and correlate with prognosis and overall survival of patients with gastrointestinal stromal tumors, helping the choice for adjuvant treatment in this patient population.